Valneva Invests $10M in LimmaTech for Clinical-Stage Shigella Vaccine

1. Deal Amount: Valneva has paid LimmaTech $10 million for a clinical-stage Shigella vaccine.
2. Clinical Trials: LimmaTech will conduct a pair of phase 2 trials for the Shigella vaccine, which are set to launch later this year.
3. Vaccine Development: The investment is part of ongoing efforts to develop a vaccine for Shigella, a significant cause of diarrheal disease globally.
4. Partnership: The collaboration between Valneva and LimmaTech aims to advance the vaccine through clinical trials and potentially bring it to market.
5. Industry Context: This deal is part of a broader trend of biotech companies investing in vaccine development and clinical-stage assets.